CRVS Corvus Pharmaceuticals Inc.

5.81
-0.12  -2%
Previous Close 5.93
Open 5.93
Price To Book 2.23
Market Cap 179,316,354
Shares 30,863,400
Volume 115,155
Short Ratio
Av. Daily Volume 214,177
Stock charts supplied by TradingView

NewsSee all news

  1. Corvus Pharmaceuticals Presents Preclinical and Initial Clinical Data from the Phase 1/1b Trial of CPI-818 at the American Society of Hematology (ASH) Annual Meeting

    BURLINGAME, Calif., Dec. 07, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted

  2. Corvus Pharmaceuticals Presents Updated Data from CPI-006 Phase 1/1b Clinical Trial at 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

     SITC presentation builds on data at ASCO in June, adding evidence supporting a new immuno-oncology approach with CPI-006 via activation of immune cells and the inhibition of adenosine production Company also presents

  3. Corvus Pharmaceuticals to Present Preclinical and Early Clinical Data from the Phase 1/1b Trial with CPI-818 at the American Society of Hematology (ASH) Annual Meeting

    BURLINGAME, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted

  4. Corvus Pharmaceuticals to Present at the 28th Annual Credit Suisse Healthcare Conference

    BURLINGAME, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted

  5. Corvus Pharmaceuticals to Webcast Investor & Analyst Event on November 8, 2019

    BURLINGAME, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1b/2 updated data due at the ASCO Genitourinary Cancers Symposium (GU) February 13-15, 2020.
CPI-444
Solid tumors - cancer
Phase 1/1b updated at SITC November 8, 2019 noted tumor regression in 4/9 patients receiving 6 mg/kg or higher.
CPI-006
Solid tumors
Phase 1/1b data due at ASH December 7, 2019 noted no dose limiting toxicities and no grade 3 or 4 adverse events observed.
CPI-818
Peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL)

Latest News

  1. Corvus Pharmaceuticals Presents Preclinical and Initial Clinical Data from the Phase 1/1b Trial of CPI-818 at the American Society of Hematology (ASH) Annual Meeting

    BURLINGAME, Calif., Dec. 07, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted

  2. Corvus Pharmaceuticals Presents Updated Data from CPI-006 Phase 1/1b Clinical Trial at 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

     SITC presentation builds on data at ASCO in June, adding evidence supporting a new immuno-oncology approach with CPI-006 via activation of immune cells and the inhibition of adenosine production Company also presents

  3. Corvus Pharmaceuticals to Present Preclinical and Early Clinical Data from the Phase 1/1b Trial with CPI-818 at the American Society of Hematology (ASH) Annual Meeting

    BURLINGAME, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted

  4. Corvus Pharmaceuticals to Present at the 28th Annual Credit Suisse Healthcare Conference

    BURLINGAME, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted

  5. Corvus Pharmaceuticals to Webcast Investor & Analyst Event on November 8, 2019

    BURLINGAME, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted

  6. Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2019 Financial Results on October 29, 2019

    BURLINGAME, Calif., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted

  7. Corvus Pharmaceuticals to Present Updated Data from CPI-006 Clinical Trial at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

    BURLINGAME, Calif., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted